<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Arhytmology that is focused on diagnostics and therapy of heart rhythm disturbances and their complications has undergone dramatic development in last 2 decades </plain></SENT>
<SENT sid="1" pm="."><plain>Widespread use of catheter ablation, introduction of implantable cardioverter-defibrillators for prevention of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> and finally, development of cardiac resynchronization therapy have lead to decreased importance of drug treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Antiarhythmic drugs remain therapy of choice in management of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and in some <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, especially in patients with implantable cardioverter-defibrillator backup </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, this review deals predominantly with a strategy of antiarythmic therapy in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and discusses possible risks </plain></SENT>
</text></document>